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Abstract: BACKGROUND Lung-protective ventilation is key in bridging patients suffering from COVID-
19 acute respiratory distress syndrome (ARDS) to recovery. However, resource and personnel limitations
during pandemics complicate the implementation of lung-protective protocols. Automated ventilation
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cally ventilated COVID-19 ARDS patients were allocated, by study-blinded coordinating staff, to either
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outcome was the overall achieved percentage of lung-protective ventilation in closed-loop versus conven-
tional mechanical ventilation, assessed minute-by-minute, during the initial 7 days and overall mechanical
ventilation time. Lung-protective ventilation was defined as the combined target of tidal volume <8 ml
per kg of ideal body weight, dynamic driving pressure <15 cmH2O, peak pressure <30 cmH2O, peripheral
oxygen saturation ฀88% and dynamic mechanical power <17 J/min. RESULTS Forty COVID-19 ARDS
patients, accounting for 1,048,630 minutes (728 days) of cumulative mechanical ventilation, allocated to
either closed-loop (n = 23) or conventional ventilation (n = 17), presenting with a median paO2/ FiO2
ratio of 92 [72-147] mmHg and a static compliance of 18 [11-25] ml/cmH2O, were mechanically ventilated
for 11 [4-25] days and had a 28-day mortality rate of 20%. During the initial 7 days of mechanical venti-
lation, patients in the closed-loop group were ventilated lung-protectively for 65% of the time versus 38%
in the conventional group (Odds Ratio, 1.79; 95% CI, 1.76-1.82; P < 0.001) and for 45% versus 33% of
overall mechanical ventilation time (Odds Ratio, 1.22; 95% CI, 1.21-1.23; P < 0.001). CONCLUSION
Among critically ill, mechanically ventilated COVID-19 ARDS patients during an early highpoint of
the pandemic, mechanical ventilation using a closed-loop mode was associated with a higher degree of
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Abstract
Background: Lung-protective ventilation is key in bridging patients suffering from COVID-19 acute respiratory distress syn-
drome (ARDS) to recovery. However, resource and personnel limitations during pandemics complicate the implementation of
lung-protective protocols. Automated ventilation modes may prove decisive in these settings enabling higher degrees of lung-
protective ventilation than conventional modes. Method: Prospective study at a Swiss university hospital. Critically ill,
mechanically ventilated COVID-19 ARDS patients were allocated, by study-blinded coordinating staff, to either closed-loop or
conventional mechanical ventilation, based on mechanical ventilator availability. Primary outcome was the overall achieved
percentage of lung-protective ventilation in closed-loop versus conventional mechanical ventilation, assessed minute-by-minute,
during the initial 7 days and overall mechanical ventilation time. Lung-protective ventilation was defined as the combined target of
tidal volume <8 ml per kg of ideal body weight, dynamic driving pressure <15 cmH2O, peak pressure <30 cmH2O, peripheral
oxygen saturation 88% and dynamic mechanical power <17 J/min. Results: Forty COVID-19 ARDS patients, accounting for
1,048,630 minutes (728 days) of cumulative mechanical ventilation, allocated to either closed-loop (n ¼ 23) or conventional
ventilation (n ¼ 17), presenting with a median paO2/ FiO2 ratio of 92 [72-147] mmHg and a static compliance of 18 [11-25] ml/
cmH2O, were mechanically ventilated for 11 [4-25] days and had a 28-day mortality rate of 20%. During the initial 7 days of
mechanical ventilation, patients in the closed-loop group were ventilated lung-protectively for 65% of the time versus 38% in the
conventional group (Odds Ratio, 1.79; 95% CI, 1.76-1.82; P < 0.001) and for 45% versus 33% of overall mechanical ventilation time
(Odds Ratio, 1.22; 95% CI, 1.21-1.23; P < 0.001). Conclusion: Among critically ill, mechanically ventilated COVID-19 ARDS
patients during an early highpoint of the pandemic, mechanical ventilation using a closed-loop mode was associated with a higher
degree of lung-protective ventilation than was conventional mechanical ventilation.
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Background
Coronavirus disease 2019 (COVID-19) triggered a surge of cri-
tically ill patients with acute respiratory distress syndrome
(ARDS) in need of mechanical ventilation.1 Optimal manage-
ment of ARDS mandates lung-protective mechanical ventilation
so as tominimize ventilator induced lung injury (VILI) and allow
for optimal recovery of the lung.2-4 Due to the high number of
patients, intensive care units (ICUs) worldwide have been over-
whelmed, leading to a shortage in the expertise and resources
needed to ensure the implementation of such lung-protective
settings.5-7 Consequently, the incidence of VILI has risen mark-
edly and mortalities in COVID-19 ARDS (CARDS) are reaching
levels not experienced for decades in the setting of ARDS.8-10
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In critical care, the implementation of tools that reduce the
strain on nursing and medical staff, while offering equal or
better benefit to the patient, may turn out to be decisive in such
a resource-intensive disease as CARDS. Closed-loop mechan-
ical ventilation could help clinicians in the systematic imple-
mentation of lung-protective ventilation in CARDS patients,
while significantly reducing their workload.
Closed-loop mechanical ventilation modes enable a fully
automatized and optimized function of the mechanical venti-
lator, thus reducing the necessity for manual adjustment.11
INTELLiVENT-ASV is such a closed-loop ventilation mode.
Based on peripheral oxygen saturation and end-tidal carbon
dioxide concentration measurements, it automatically adjusts
minute ventilation, the fraction of inspired oxygen (FiO2) and
the positive end-expiratory pressure (PEEP) breath-
by-breath.11 INTELLiVENT-ASV has been shown to safely
ventilate patients in a variety of pathologies and to maintain
ventilation settings and lung mechanics within the limits of
protective mechanical ventilation, while reducing the necessity
for medical and nursing adjustment.12-14
The objective of the present study was to assess the perfor-
mance, in terms of lung-protective ventilation, of a closed-loop
ventilation mode as compared to conventional mechanical ven-
tilation in the resource-constrained setting of the COVID-19
pandemic.
Methods
This prospective study was performed between March and May
2020 at the Institute of Intensive Care Medicine of the Univer-
sity Hospital Zurich, an academic tertiary care referral center.
The study was approved by the cantonal ethics committee of
Zurich (BASEC: 2020-01681) and informed consent was
obtained from the patients or from their next of kin. The study
complies with the Declaration of Helsinki, the Guidelines on
Good Clinical Practice (GCP-Directive) issued by the
European Medicines Agency as well as with Swiss law and
regulatory authority requirements.
Population
Patients were prospectively included in this study if they pre-
sented with (I) a SARS-CoV-2 infection that was laboratory
confirmed by nucleic acid amplification according to the
WHO-issued testing guidelines,15 and (II) a critical manifesta-
tion of COVID-19 requiring admission to an intensive care unit
and treatment with invasive mechanical ventilation due to pro-
found hypoxemia, complying with the Berlin definition for
ARDS.16
Study Design, Blinding and Ventilator Allocation
In the setting of the COVID-19 pandemic, resources at the
Institute of Intensive Care Medicine had to be expanded to
allow for care of a higher number of invasively ventilated
COVID-19 patients. Therefore, in addition to the standard
Hamilton-S1 (Hamilton Medical AG, Switzerland) mechani-
cal ventilator, Draeger Evita Infinity V500 machines
(Draegerwerk AG, Germany) had to be employed to mechani-
cally ventilate COVID-19 patients. The standard mode of
ventilation employed on the Hamilton-S1 ventilator was
INTELLiVENT-ASV 1.1 (closed-loop ventilation), and
Biphasic Positive Airway Pressure Ventilation on the Draeger
Evita Infinity V500 (conventional ventilation). Weaning
from the Hamilton ventilator was approached via the
INTELLiVENT-ASV mode. For the Draeger ventilator,
Biphasic Positive Airway Pressure and Spontaneous Continu-
ous Positive Airway Pressure ventilation could be used. Venti-
lation times on other ventilation modes, during patient
transport and during interventions, were disregarded in the final
analysis to prevent potential biases. Physician and nursing staff
in charge of treatment and care in the ICU were the same for
both types of mechanical ventilator; no differentiation or split-
ting of teams dependent on ventilator expertise was underta-
ken. Medical and nursing staff were familiar with the use of
both devices and ventilation modes as part of their daily
routine, and had received an intensified refresher course on
mechanical ventilation focusing on lung-protective ARDS ven-
tilation in both closed-loop ventilation and conventional venti-
lation modes at the beginning of the pandemic. Institutional
standard procedures were the same for both closed-loop and
conventional mechanical ventilation, including but not limited
to the proning of patients with a partial pressure of arterial
oxygen (paO2) over FiO2 ratio (P/F ratio) <200 mmHg, the use
of neuromuscular blocking agents in patients with a P/F ratio
<150 mmHg or presenting an uncontrollable respiratory drive
and vigorous breathing efforts under deep sedation, as well as
the use of an esophageal pressure probe in patients at the limit
of lung-protective ventilation or with a clinically assessed
abnormal chest-wall compliance.
Patients were allocated, at the time-point of ICU admission,
to either type of mechanical ventilator based on the availability
of the latter by coordinating staff unaware of this study, without
any further judgment or knowledge of the patients’ condition
influencing this decision. Medical and nursing staff, including
consulting physicians, were fully blinded to the existence of the
present study. Further, the study team was blinded to the initial
respirator allocation and had no influence on the decision.
Data Collection and Lung-Protective Mechanical
Ventilation Definition
All mechanical ventilators were attached to the patient data man-
agement system (MetaVision, iMDsoft, Israel) enabling
a prospective, minute-by-minute collection of all mechanical
ventilator settings and measurements. Changes in ventilator set-
tings (respiratory rate, FiO2, PEEP, inspiratory pressure, support
pressure, target shifts, PASV limit and INTELLiVENT-ASV
controllers) were algorithmically assessed on a minute-by-
minute basis; thus, non-equal, temporally concomitant settings
were noted as a change. To assure optimal ventilation and oxy-
genation of all patients, at least 1 blood gas analysis per 6 hours
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ICU was performed. Static driving pressure was measured at
the time-point of endotracheal intubation as the difference of an
inspiratory-and an expiratory-hold maneuver, subsequently O
static compliance was calculated as tidal volume static driving
pressure. However, in order to enable a continuous, minute-by-
minute assessment of driving pressure and mechanical power,
we chose to employ their dynamic approximations in analogy to
the previously published study by Urner et al.17 Peak inspiratory
pressure was thus employed as a surrogate for plateau pressure.
Consequently dynamic driving pressure was calculated as peak
inspiratory pressure  positive end expiratory pressure,
dynamic compliance as tidal volumeO dynamic driving pres-
sure and dynamic mechanical power as 0.098 respiratory rate
 tidal volume  (peak inspiratory pressure (0.5  dynamic
driving pressure)).
Lung-protectivemechanical ventilation was defined and insti-
tutionally targeted as: a maximal tidal volume of 6-8 ml per kg of
ideal body weight.18,19 a driving pressure <15 cmH2O,
20 a pla-
teau pressure <30 cmH2O,
21 a paO2 7.33 kPa or a peripheral
oxygen saturation (SpO2)88%
22,23 under permissive hypercap-
nic ventilation with a lower pH limit of 7.25.24 Further, a
mechanical power <17 J/min was defined as lung-protective for
the setting of this study.17,25
Statistical Analysis
Due to the breakthrough nature of this cohort study during the
ongoing health crisis, no power calculations were undertaken.
Comparisons of population characteristics were performed
using the Wilcoxon Signed Rank and chi-squared test, as
appropriate. A 2-sided P < 0.05 was considered statistically
significant. For longitudinal analysis of mechanical ventilator
parameters, lung mechanics and blood gas analyses, differ-
ences between time points and ventilation modes were tested
using linear mixed effects model analysis. As independent vari-
able fixed effects, time point and ventilation mode were
entered into the model, respectively, with and without interac-
tion terms, which were retained only if they were found to
contribute to the model. As random effects, intercepts for sub-
jects as well as per-subject random slopes for the effect on
dependent variables were employed. P values were calculated
using a likelihood ratio test of the full model, with the effect in
question, against a “null model,” without the effect in question.
P values for individual fixed effects were obtained by Sat-
terthwaite approximation in a multi-dimensional model com-
prising time point and outcome status. Statistical analysis was
performed via a fully scripted data management pathway using
the R environment for statistical computing version 3.6.1.26
Values are given as medians with interquartile ranges or counts
and percentages as appropriate.
Results
Demographics
Forty-seven patients with CARDS were admitted to the inten-
sive care unit during the study period. Of these, 40 patients
required invasive mechanical ventilation, were included in the
study and allocated by study-blinded coordinating staff to either
conventional ventilation (ConV) in 17 cases or closed-loop ven-
tilation (CLoop) in 23 cases, as illustrated in Figure 1. At admis-
sion, patients were characterized by a P/F ratio of 92 [72-147]
mmHg and a static compliance of 18 [11-25] cmH2O/ L, as
presented in Table 1. Baseline characteristics were comparable
for the 2 groups (Table 1). Overall time on mechanical ventila-
tion was 11 [4-25] days and 28-day mortality amounted to
20% (Table 1). Only 1 patient died due to refractory respiratory
failure, the leading causes of death were coagulopathy associ-
ated, with 4 patients deceasing due to intestinal ischemia and
1 due to central pulmonary embolism with right heart failure
(Supplemental Table e1).
Overall Mechanical Ventilation
Overall, 1,048,630 minutes or 728 days of cumulative mechan-
ical ventilator time were analyzed (Table 2). Patients in the
CLoop group were ventilated with slightly higher tidal volumes
normalized to the ideal body weight (IBW), leading to lower
partial pressures of arterial carbon dioxide (paCO2) at a clini-
cally comparable pH as opposed to the ConV group (Table 2).
Regarding oxygenation, the CLoop group presented overall
lower paO2 levels at lower PEEP and FiO2 settings than did
the ConV group, but was nevertheless characterized by a higher
P/F ratio with 199 [152-251] mmHg versus 168 [126-216]
mmHg in the ConV group (P < 0.001) (Table 2).
Further, and as shown in Table 2, peak inspiratory pressure,
dynamic driving pressure as well as dynamic mechanical
power could be held systematically lower in the CLoop than
in the ConV group (P < 0.001). This was accompanied by a
decreased alveolar dead space and alveolo-arterial gradient in
the CLoop group (P < 0.001) (Table 2).
Initial CARDS Mechanical Ventilation
During the initial 7 days post intubation, patients in the CLoop
group experienced systematically lower peak inspiratory pres-
sures (P < 0.001), respiratory rate (P < 0.001), dynamic driving
pressure (P < 0.001) and dynamic mechanical power
(P < 0.001), while achieving higher dynamic compliance
(P < 0.01) and lower alveolar dead space (P < 0.002) than
did patients in the ConV group, as evidenced in Figure 2, Table
2, Supplemental Figures e1, e2 and Supplemental Tables e2,
e3, e4.
Lung-Protective Ventilation
The dynamic driving pressure in the CLoop group was main-
tained at <15 cmH2O for 84% of the time during the initial
week, and 66% for the overall ventilation time, as opposed to
51% (P < 0.001) and 49% (P < 0.001), respectively, for
dynamic driving pressures in the ConV group (Figure 3,
Supplemental Tables e5, e6). Further, dynamic mechanical
power could be held to <17 J/min for 79% of the ventilation
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time during the initial week in the CLoop group, compared to
50% achieved in the ConV group (P < 0.001); this difference
was also patent when the overall ventilation time between
groups was compared (P < 0.001). Additionally, the percentage
of time with a peak inspiratory pressure <30 cmH2O
(P < 0.001) was also higher in the CLoop group. Simultane-
ously, paO2 levels remained 7.33 kPa for 99% and the SpO2
88% for 99% of the ventilation time in the CLoop group
versus 99% (P < 0.001) and 97% (P < 0.001) in the ConV
group, respectively. Finally, patients in the CLoop group were
successfully ventilated in a fully protective fashion, with con-
joint tidal volumes <8 ml/kg IBW, dynamic driving pressures
<15 cmH2O, peak inspiratory pressures <30 cmH20, SpO2
88% and dynamic mechanical power <17 J/min, over 45%
of the time, 63% during the first week, as opposed to 33%
(OR 1.79; 95% CI 1.76-1.82; P < 0.001) and 38% (OR 1.22;
95% CI 1.21-1.23; P < 0.001), respectively, in the ConV group.
Changes in Settings
In patients ventilated in the ConV group 7 [3-12] changes per
day had to be manually implemented to adapt mechanical ven-
tilator settings as opposed to 4 [2-7] in the CLoop group
(P ¼ 0.02). In comparison, the automated algorithm in
the CLoop group adapted the ventilator settings every 2.8
[2.3-3.6] minutes.
Discussion
In this prospective study, closed-loop mechanical ventilation
(CLoop) was compared with conventional mechanical ventila-
tion (ConV) in COVID-19 ARDS (CARDS) on a minute-by-
minute basis. The CLoop group was fully protectively ventilated
concerning tidal volume, driving pressure, peak inspiratory pres-
sure, peripheral oxygen saturation and mechanical power, for
65% of the first week and 45% of their overall ventilation time,
as opposed to 38% and 33%, respectively, for those in the ConV
group. This was achieved with a concomitant decrease in the
need for manual adjustment of the ventilator settings in the
CLoop compared to the ConV group.
Protective invasive mechanical ventilation has become a
clear goal in ARDS therapy in order to limit strain to the
“baby lung” and prevent VILI.3 In this setting, reduced tidal
volume ventilation patterns with 4 to 8 ml/kg IBW tidal
volumes have become standard of care.18,19 Nonetheless, the
implementation of these standards is still not universal; in the
recent LUNG SAFE study only two-thirds of the ARDS
patients received tidal volumes below 8 ml/kg IBW27 and
recent data show only 23% of patients with CARDS being
ventilated with tidal volumes below 6 ml/kg IBW.28 The pres-
ent study reports a limitation of tidal volumes below 8 kg/ml
IBW for 90% and below 6 ml/kg for 57% of the mechanical
ventilation time in the ConV group, reflecting the excellent
Figure 1. Study flow diagram.
4 Journal of Intensive Care Medicine XX(X)
training and understanding of protective ventilation among
ICU staff. Nonetheless, and regardless of the evident profi-
ciency of the medical and nursing staff, CLoop was superior
to ConV concerning settings for inspiratory pressure and
dynamic driving pressure. These 2 variables act as surrogate
parameters for transpulmonary pressure and pulmonary disten-
sion, and their limitation at 30 cmH2O
21 and 15 cmH2O,
17,20
respectively, has been correlated with systematic mortality
reductions in ARDS. Further, recent research has emphasized
the importance of elevated cycling frequencies as amplifiers of






N ¼ 23 P
Demographics
Age [years] 61 [54-70] 59 [56-66] 66 [54-72] 0.331
Sex [male] 33 (83) 15 (88) 17 (78) 0.689
BMI [kg m-2] 28 [26-31] 29 [27-31] 27 [25-29] 0.151
SAPS II 36 [27-47] 36 [30-45] 36 [27-47] 0.837
SOFA 9 [6-10] 8 [6-10] 9 [6-10] 0.901
PaO2/ FiO2 [mmHg] 92 [72-147] 86 [66-137] 99 [77-147] 0.639
Time from first Symptoms to ICU Admission
[days]
9 [5-14] 9 [6-15] 8 [5-10] 0.702
Time to ICU Admission from Hospital
Admission [days]
0 [0-3] 1 [0-3] 0 [0-1] 0.126
Need for Vasopressors 19 (48) 8 (47) 11 (48) 0.899
Comorbidities
Ischemic Heart Disease 8 (20) 1 (6) 7 (30) 0.347
Arterial Hypertension 23 (58) 9 (53) 14 (61) 0.859
Diabetes Mellitus 17 (43) 6 (35) 11 (48) 0.639
Chronic Pulmonary Disease 7 (18) 4 (24) 3 (13) 0.659
Chronic Renal Insufficiency 11 (28) 4 (24) 7 (30) 0.9
Solid Tumor 4 (10) 3 (18) 1 (4) 0.394
Immunosuppressionb 7 (18) 4 (24) 3 (13) 0.659
Laboratory Parameters
White Blood Cell Count [G/l] 8.2 [6.3-12.0] 7.3 [5.2-10.0] 10.0 [6.4-13.4] 0.123
Interleukin-6 [ng/l] 136 [90-507] 135 [73-796] 144.5 [91-238] 0.629
CRP [mg/l] 192 [102-283] 124 [62-245] 232 [165-287] 0.089
Creatinine [mmol/l] 91 [72-144] 91 [80-180] 91 [70-128] 0.941
D-Dimer [mg/l] 2725 [1020-4178] 1190 [720-3048] 3195 [1758-5668] 0.088
Arterial Blood Gas Analysis
pH 7.28 [7.24-7.33] 7.30 [7.25-7.36] 7.28 [7.22-7.31] 0.172
paO2 [kPa] 8.3 [7.8-9.1] 8.3 [7.9-8.9] 8.3 [7.8-9.2] 0.825
paCO2 [kPa] 6.8 [6.0-7.5] 6.8 [6.0-7.7] 6.8 [6.2-7.4] 0.847
HCO3 [mmol/l] 23 [22-24] 23 [23-24] 24 [22-25] 0.988
Lactate [mmol/l] 0.9 [0.7-1.2] 0.9 [0.7-1.1] 0.9 [0.7-1.2] 1
Mechanical Ventilation Parameters
FiO2 [%] 98 [95-100] 100 [96-100] 97 [95-100] 0.193
PEEP [cmH2O] 15 [14-17] 15 [11-16] 16 [14-17] 0.245
Tidal Volume/ IBW [ml/kg] 7.5 [6.5-8.8] 6.6 [6.5-8.1] 8.0 [6.8-9.0] 0.065
Static Driving Pressure [cmH2O] 17 [15-20] 21 [17-24] 16 [14-18] 0.001
Respiratory Rate [1/min] 28 [23-32] 30 [27-34] 27 [22-32] 0.079
Minute Volume Ventilation [l/min] 9.6 [8.4-11.0] 11.2 [8.6-13.8] 9.5 [8.3-10.4] 0.095
Peak Inspiratory Pressure [cmH2O] 29 [26-33] 33 [30-36] 27 [25-31] 0.005
Static Mechanical Power [J/min] 21 [19-24] 24 [21-31] 19 [16-22] 0.004
Static Compliance [ml/cmH2O] 18 [11-25] 16 [11-20] 21 [12-26] 0.203
Outcome
Duration of Mechanical Ventilation [days] 11 [4-25] 12 [6-24] 10 [4-23] 0.837
Length of ICU stay [days] 18 [8-32] 19 [7-32] 18 [9-33] 0.547
28-Day Mortality 8 (20) 2 (12) 6 (26) 0.472
Abbreviations: BMI, Body Mass index; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; CRP, C-reactive protein; PCT,
Procalcitonin; LDH, Lactate dehydrogenase; HCO3, Bicarbonate; paO2, partial pressure of arterial oxygen; paCO2, partial pressure of arterial carbon dioxide;
FiO2, Fraction of inspired oxygen; PEEP, Positive End-Expiratory Pressure; IBW, Ideal Body Weight; ICU, Intensive Care Unit.
aQuantitative data are expressed as median [interquartile range] or counts (and percentages) as appropriate.
b Immunosuppression was defined as any of the following: Hematological Malignancy, Human Immunodeficiency Virus, Hepatitis B or C, Prescribed Immunosup-
pressive Medication.
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the static strain induced by tidal volumes and driving pressures
leading to the stress failure of stress-bearing alveolar micro-
elements.3,29 The observed reduced respiratory rate in the
CLoop group during the acute phase of CARDS ventilation,
as opposed to the higher respiratory frequencies in the ConV
group, could thus be a further protective factor. Interestingly,
and in contrast to ConV, CLoop enabled normoxic ventilation
at higher P/F ratios while reducing FiO2 levels. Elevated
FiO2 settings have been previously postulated as an exacerbat-
ing variable to alveolar barrier dysfunction, aggravating the
degree of VILI, while their limitation has shown protective
effects.30-33
The concept of mechanical power is a relatively new and
holistic approach to quantifying the energetic strain delivered
to the lung during ventilation.34,35Mechanical power combines
the effects of all main ventilatory variables, and powers above
17 J/min have been associated with worse outcomes in
ARDS.17,25 Even though mechanical power calculation is not
included in the CLoop algorithm, this type of ventilation mode
managed to limit mechanical power to under 17 J/min for 79%
of ventilation time while ConV did so for only 50% of the time,
a value similar to the mechanical power reported in large
ARDS cohorts.17 Interestingly, the percentage of time under
lung-protective mechanical ventilation in the CLoop group,
especially regarding mechanical power, was reduced during
the first week in comparison to the overall time, probably indi-
cating the difficulty of the closed-loop algorithm to counter-
balance spontaneous ventilation.
Table 2. Arterial Blood Gas Analyses and Mechanical Ventilator Parameters Over the Course of Mechanical Ventilation.a
Overall population, N ¼ 40 Conventional ventilation, N ¼ 17
Closed loop ventilation,
N ¼ 23 P
Initial 7 Days of Mechanical Ventilation
n [minutes] 348319 173626 174693
pH 7.37 [7.31-7.41] 7.37 [7.31-7.42] 7.36 [7.31-7.40] <0.001
paO2 [kPa] 9.5 [8.8-10.5] 9.8 [8.8-10.9] 9.3 [8.8-10.2] <0.001
SpO2 [%] 93 [91-95] 94 [92-96] 93 [91-94] <0.001
paCO2 [kPa] 5.9 [5.3-6.8] 5.9 [5.2-6.8] 6.0 [5.3-6.8] 0.954
PaO2/ FiO2 Ratio [mmHg] 165 [121-209] 161 [115-207] 169 [127-210] 0.005
FiO2 [%] 43 [35-55] 45 [35-57] 42 [33-54] <0.001
PEEP [cmH2O] 11 [9-14] 11 [9-14] 11 [9-14] <0.001
Tidal Volume [ml] 385 [304-446] 349 [252-429] 394 [321-450] <0.001
Tidal Volume/ IBW [ml/kg] 5.7 [5.1-6.5] 5.7 [4.8-6.6] 5.8 [5.3-6.5] <0.001
Respiratory Rate [1/min] 23 [18-26] 24 [20-27] 21 [18-25] <0.001
Minute Ventilation [l/min] 8.6 [6.8-10.5] 9.5 [7.3-11.2] 7.9 [6.8-9.5] <0.001
Peak Inspiratory Pressure [cmH2O] 25 [21-28] 27 [23-30] 23 [20-26] <0.001
Dynamic Driving Pressure [cmH2O] 13 [10-16] 15 [12-19] 12 [10-14] <0.001
A-a Gradient [mmHg] 184 [125-286] 200 [137-302] 172 [117-266] <0.001
Alveolar Dead Space [ml] 41 [19-74] 45 [22-78] 40 [18-70] 0.002
Dynamic Compliance [ml/ cmH2O] 29. [22-40] 25 [20-35] 33 [24-43] <0.001
Dynamic Mechanical Power [J/min] 14 [11-19] 17 [10-23] 13 [11-16] <0.001
Overall Time on Mechanical Ventilation
n [minutes] 1048630 415047 633583
pH 7.38 [7.33-7.43] 7.38 [7.32-7.43] 7.38 [7.33-7.42] <0.001
paO2 [kPa] 9.8 [9.0-11.0] 9.9 [9.0-11.1] 9.7 [9.0-10.9] 0.002
SpO2 [%] 94 [92-96] 94 [92-96] 94 [92-96] <0.001
paCO2 [kPa] 6.0 [5.1-7.0] 6.0 [5.1-7.2] 6.0 [5.0-6.9] <0.001
PaO2/ FiO2 Ratio [mmHg] 185 [141-241] 168 [126-216] 199 [152-251] <0.001
FiO2 [%] 38 [30-50] 42 [34-54] 36 [30-47] <0.001
PEEP [cmH2O] 9 [6-12] 9 [7-12] 9 [6-11] <0.001
Tidal Volume [ml] 394 [304-482] 355 [278-450] 406 [317-492] <0.001
Tidal Volume/ IBW [ml/kg] 5.8 [4.9-6.8] 5.8 [4.7-6.9] 5.8 [4.9-6.7] <0.001
Respiratory Rate [1/min] 25 [20-28] 25 [20-28] 24 [20-29] 0.118
Minute Ventilation [l/min] 9.6 [7.4-11.9] 9.9 [7.5-12.0] 9.3 [7.4-11.9] <0.001
Peak Inspiratory Pressure [cmH2O] 24 [19-28] 26 [20-29] 23 [19-27] <0.001
Dynamic Driving Pressure [cmH2O] 14 [10-18] 15 [12-19] 13 [10-17] <0.001
A-a Gradient [mmHg] 153 [98-234] 184 [123-278] 134 [90-204] <0.001
Alveolar Dead Space [ml] 42 [13-76] 47 [15-82] 40 [12-74] <0.001
Dynamic Compliance [ml/ cmH2O] 27 [19-42] 25 [19-38] 29 [20-44] <0.001
Dynamic Mechanical Power [J/min] 15 [10-20] 16 [9-22] 14 [10-19] <0.001
Abbreviations: paO2—partial pressure of arterial oxygen; SpO2, Peripheral oxygen saturation; paCO2, Partial pressure of arterial carbon dioxide; FiO2, Fraction of
inspired oxygen; PEEP, Positive End-Expiratory Pressure; IBW, Ideal Body Weight; A-a Gradient, Alveolar-arterial Gradient.
aQuantitative data are expressed as median [interquartile range].
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Integrating lung-protective ventilation approaches into rou-
tine mechanical ventilation is a complex and resource-intensive
endeavor, even for experienced clinicians and nurses.27,36 The
pandemic triggered by SARS-CoV-2 has overwhelmed hospi-
tals, leading to a lack of personnel and resources in ICUs.5-7
Mortalities in mechanically ventilated CARDS patients have
been reported to oscillate between 20%-80% in this set-
ting,1,8,28,37,38 with most lying substantially above the 30%
reported in classic ARDS.10 Reasons for the variability of mor-
tality are manifold, probably reflecting the heterogeneity of
treatment strategies, especially regarding off-label therapies,
patient triage before ICU, variable degrees of resources and
staffing limitation as well as ventilation strategies, including
ventilator sharing, among others.1,8,28,37-39 Nonetheless, the
elevated incidence of barotraumas in CARDS as compared to
classical ARDS may mainly be rooted in the exhaustion of
personal resources, coupled with the recruitment of staff who
are inexperienced in ARDS treatment.8,9,40 The thorough
implementation of lung-protective protocols could explain the
exceptionally low 28-day mortality of only 20% in this cohort.
Most notably no ventilator associated barotraumas were
observed in this cohort and only 1 patient died of refractory
respiratory failure.
In analogy to previous studies on CLoop, the number of
manual changes in mechanical ventilator settings by caregivers
was lower with CLoop than with ConV.12 This added effi-
ciency could reduce strain on nursing and medical staff, espe-
cially within the framework of the COVID-19 pandemic.
Further, it allows inexperienced ICU staff to implement lung-
protective ventilation strategies without the need for exhaustive
training and considerations of the high heterogeneity of
CARDS.2,41 Experienced caregivers are rare and the imple-
mentation of their know-how is resource-intensive.36
The present study has to acknowledge certain limitations.
First, this study was not a classic and truly randomized con-
trolled trial; nevertheless, the study design chosen was devised
to maximally reduce biases. Second, the primary end-point of
the study, albeit of pathophysiological relevance, does not
prove a clinical benefit of CLoop over ConV. Nonetheless, this
study describes continuous, minute-by-minute sampled
Figure 2. (A to F) Main ventilatory characteristics of COVID-19 ARDS patients ventilated with conventional ventilation mode versus closed
loop ventilation over the first week of ventilation. For ease of visualization, individual patient data were averaged into 6-hour intervals. Lines
represent median values, shaded areas the interquartile ranges.
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ventilatory data, something unaccomplished before over such a
long period of mechanical ventilation in ARDS. This, in turn,
allows a faithful representation of both ventilation strategies
over time, as opposed to the reporting of daily sampled ventila-
tion data, and counterbalances the relatively low number of
recruited patients. Third, the relevance of the reduction in ven-
tilator interactions described was not directly correlated to the
bedside experience of the ICU staff; as such, the degree of
reduction in effective strain on medical and nursing personnel
is not quantifiable. Fourth, it can be argued, that the present
study only regarded CLoop comparing it with pressure-
controlled ventilation, and disregarding the still widely used
volume-controlled ventilation. However, there is no clear evi-
dence favoring any mode over pressure control in ARDS.42,43
Fifth, the use of peak pressure as a surrogate parameter for
plateau pressure may be a relevant confounder for the inter-
pretability of the data. Nevertheless, and as previously shown,
dynamic driving pressure and mechanical power have a clinical
repercussion on outcome similar to static driving pressure and
mechanical power.17 Further, there is no current method for
faithfully assessing static plateau pressure in a continuous
approach. Sixth, it could be argued that ICU staff were not
accustomed to pressure-controlled ventilation and lung-
protective strategies, leading to the observed inferiority of
ConV. However, the implementation of mechanical ventilation
refreshers for the ICU staff previous to this study’s initiation as
well as the high degree of implementation of lung-protective
strategies in the ConV group compared to what is mentioned in
the literature, argue against this point. Finally, while the imple-
mentation and acceptance of closed-loop ventilation is wide-
spread in the ICU setting in which this study was performed,
the de-novo implementation of this tool in other ICUs may face
resistance due to its novelty and an intrinsic reluctance to use
automatic tools in ICU settings. As shown here, the safety and
efficacy of closed-loop ventilation as well as the reduction of
workload should be strong enough arguments to support a
supervised implementation of this technology, especially in the
setting of a pandemic.
Conclusion
In conclusion, closed-loop ventilation, when compared to con-
ventional mechanical ventilation, is associated with a higher
degree of lung-protective ventilation, coupled with less
hypoxemic time, while reducing the number of mechanical
ventilator setting adjustments necessary in CARDS during an
early highpoint of the COVID-19 pandemic.
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